You don’t have products yet

View Products

Distinguish Triple Negative Breast Cancer using BioGenex IHC Biomarker

Blog: Distinguish Triple Negative Breast Cancer using BioGenex IHC Biomarker

Triple-negative breast cancer (TNBC) is a highly heterogeneous subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor2 (HER2) amplification. It accounts for approximately 10-20% of all breast cancer cases and tends to be more aggressive. This sub-type tends to be more aggressive, with higher recurrence rates, greater metastatic potential, and lower overall survival compared to other breast cancers. Unfortunately, this sub-type has a poor prognosis compared to other subtypes. TNBC does not express either of the three ER, PR, or HER2. This unique molecular profile makes it challenging to target with existing therapies. 

Triple Negative Breast Cancer

Due to the lack of specific targets (such as ER or HER2), endocrine therapy and HER2-targeted treatments are ineffective for TNBC. Molecular-targeted therapies have limited success, and there is no standard treatment. Researchers are exploring genetic biomarkers for better understanding of TNBC and identify potential therapeutic targets. Accurate molecular classification is crucial for risk categorization, treatment decisions, and surveillance. 

BioGenex offers potential biomarkers associated with TNBC:  

TP53 (Tumor Protein 53): Mutations in TP53 are common in TNBC. TP53 status could impact treatment decisions. 

 EGFR (Epidermal Growth Factor Receptor): EGFR is often over expressed in TNBC and may serve as a therapeutic target. 

 VEGFR (Vascular Endothelial Growth Factor Receptor): VEGFR plays a role in angiogenesis and tumor growth. Targeting VEGFR may be beneficial in TNBC treatment. 

 ALDH1 (Aldehyde Dehydrogenase 1): ALDH1 is a potential stem cell marker in TNBC.  

Interleukins: Certain interleukins such as IL-6 are associated with TNBC progression and inflammation. 

Remember that TNBC is heterogeneous, and individual patient profiles may vary. Research continues to identify novel biomarkers and therapeutic targets for this challenging subtype. 

BioGenex offers ready-to-use (RTU) & concentrated forms of antibodies for both manual & automated systems which are best-in-class for clinic-pathological diagnosis & drug discovery. It enables pathologists & clinicians to precisely diagnose and improve life expectancy. 

Subscribe to our newsletter

Don't miss out on the latest news, exclusive updates, and special offers.

Do you have questions? Contact Us